Drugs / Dapansutrile
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05880355 | Apr 2026 → Dec 2028 expected | myocardial infarction | University of Virginia | Not yet recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT03534297 | May 2018 → Nov 2019 | systolic heart failure | Olatec Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02134964 | Jun → Dec 2014 | — | Olatec Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04971499 | Sep 2022 → Apr 2027 expected | melanoma | April Salama, M.D. | Active not recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06047262 | Jul 2024 → Jul 2028 expected | type 2 diabetes mellitus | Marc Donath | Recruiting | No outcome recorded |
| Phase 2 | NCT04540120 | Sep 2020 → Jul 2022 | COVID-19, cytokine release syndrome | Olatec Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03595371 | May 2018 | Schnitzler syndrome | Olatec Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT02104050 | Apr 2014 → Aug 2015 | osteoarthritis, pain agnosia | Olatec Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01768975 | Jan → Aug 2013 | osteoarthritis, knee | Olatec Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05658575 | Jan 2023 → Dec 2026 expected | arthritic joint disease, gout | Olatec Therapeutics, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01636141 Comparator | Jun → Aug 2012 | — | Olatec Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07157735 Comparator | Feb 2026 → May 2027 expected | Parkinson disease | Cambridge University Hospitals NHS Foundation Trust | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-20 | Olatec Therapeutics, Inc. | Results Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson’s Studies olatec.com ↗
The results presented by Dr. Stefanova demonstrated that chronic oral treatment with dapansutrile, produces broad, durable, and clinically relevant disease-modifying effects in two translational mouse models of Parkinson’s disease (PD). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-03-24 | Olatec Therapeutics, Inc. | First Parkinson’s Patients Treated in Landmark Phase 2 Trial of Dapansutrile, Expanding a Leading Oral NLRP3 Inhibitor into Neurological Diseases olatec.com ↗ |
| 2026-01-20 | Olatec Therapeutics, Inc. | Olatec Therapeutics Presented Preclinical Evidence of Disease-Modifying Activity with Dapansutrile in its Parkinson’s Studies olatec.com ↗ |
| 2024-07-11 | Olatec Therapeutics, Inc. | First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor Dapansutrile olatec.com ↗ |
| 2020-10-27 | Olatec Therapeutics, Inc. | Olatec Therapeutics Enrolls its First Patients in a Phase 2 Clinical Trial in COVID-19 with its Selective NLRP3 Inhibitor Oral Dapansutrile olatec.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dapansutrile | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03595371 ↗ |
| Known as | Dapansutrilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989943 ↗ |
| Known as | OLT1177 | “The aim of this study was to determine the safety of an oral inhibitor of the NLRP3 inflammasome, dapansutrile (OLT1177), in patients with heart failure and reduced ejection...” PMID 33235030 ↗ Oct 20205“DAPA-PD is a randomised double-blind, placebo-controlled phase II trial investigating the safety and tolerability of dapansutrile (OLT1177), an NLRP3 inhibitor, in people with early PD” NCT07157735 ↗ |
| Known as | OLT1177 capsules | “OLT1177 capsules” NCT03595371 ↗ |
| Known as | OLT1177 Gel | “OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee” NCT01636141 ↗ |
| Action | Inhibit | “oral inhibitor of the NLRP3 inflammasome” PMID 33235030 ↗ Oct 2020 |
| Modality | Small molecule | — CHEMBL3989943 ↗ |
| Route | Topical | “administered topically” NCT01636141 ↗ |
| Target | NLRP3 | “oral inhibitor of the NLRP3 inflammasome” PMID 33235030 ↗ Oct 2020 |